EUDRAC will be exhibiting at the annual DIA Annual Meeting in Boston, United States of America from 24th to 28th June 2018. Our team would be pleased to welcome you at booth number 1143 to discuss your potential regulatory affairs, pharmacovigilance and publishing needs. A member of our Management...
Read moreEUDRAC recently collaborated on a successful PRIME application with The EspeRare Foundation , a Swiss not-for profit Biotech Company which develops existing therapies to address severe unmet therapeutic needs in rare diseases. The application was for a protein replacement therapy (ER004) for X-...
Read moreEUDRAC attended the MHRA GPvP Symposium on Pharmacovigilance in May 2018. Click here for an document outlining of some of the common inspection findings. Please contact us directly for further information or for queries on how EUDRAC can assist you with your pharmacovigilance needs.
Read moreEUDRAC recently attended the DIA Europe meeting in Basel. One of the most popular sessions was 'EMA Relocation and Implication for Centralised Activities’. Please see here for a summary of the discussions.
Read moreEUDRAC Ltd is extremely proud to have won a 2018 Queen’s Award for Enterprise in the International Trade category. The Queen’s Awards for Enterprise are the UK’s most prestigious business awards, recognising and celebrating business excellence across the UK. Her Majesty The Queen publicly announced...
Read moreIn March 2018, the EMA published a EudraVigilance Dos and Don’ts document with the aim to reduce Individual Case Safety Report (ICSR) processing errors. This document was based on the initial operational experience with EudraVigilance (EV) and highlights the following Dos and Don’ts when processing...
Read moreThis website uses cookies to ensure you get the best experience on our website. Read more.